Abstract
Persistent viral eradication or suppression through a defined course of Pegylated-interferon (PegIFN) or the administration of a long-term potent nucleot(s)ide analogues (NUCs) can impact positively the natural course of HBV infection by preventing disease progression. Despite the higher rates of off-therapy response achieved with PegIFN compared with NUC, its benefits are restricted to a subgroup of patients only. To increase the rates of patients who may benefit from PegIFN treatment, minimizing the adverse events, careful patient selections based on baseline features and on treatment HBsAg kinetics for individual treatment optimization are required.
Original language | English |
---|---|
Pages (from-to) | 425-443 |
Number of pages | 19 |
Journal | Clinics in Liver Disease |
Volume | 17 |
Issue number | 3 |
DOIs | |
Publication status | Published - Aug 2013 |
Keywords
- Chronic hepatitis B
- HBsAg levels
- HBV DNA
- IL28B polymorphism
- Pegylated interferon
- Sustained response
ASJC Scopus subject areas
- Hepatology